MDB5
MDB5 is a Hedgehog pathway and Smoothened inhibitor that binds to the 7-TM domain of Smo. MDB5 reduces hepatic stellate cell activation, extracellular matrix-related gene expression, collagen deposition, hydroxyproline content and epithelial-mesenchymal transition, and prevents sinusoidal endothelial cell capillarization. MDB5 induces G1 and S phase cell cycle arrest, triggers apoptosis by upregulating Bax and downregulating Bcl-2, and also decreases oxygen consumption rate, glucose uptake, transglutaminase activity and fibronectin matrix assembly. MDB5 reduces the levels of liver injury markers, hepatic triglyceride deposition and hepatic steatosis, restores the tissue structure of the kidney and spleen, and inhibits pancreatic tumor growth without causing body weight loss. MDB5 can be loaded into PEG-PCC-g-DC micelles, achieving high drug loading, sustained release, improved water solubility, enhanced cellular uptake and optimized hepatic distribution, with good tolerance in mice. MDB5 is applicable to research related to alcohol-associated liver disease, liver fibrosis and pancreatic cancer.
For research use only. We do not sell to patients.
- CAS No.: 2922221-22-3
- Formula: C31H23Cl2N5O2
- Molecular Weight:568.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
MDB5 (50 μM) inhibits ethanol-induced upregulation of Gli1 and Gli2 expression in AML12 mouse hepatocytes[1].
MDB5 (50 μM; 48 h) regulates the expression of fibrosis-related genes (Smad7, Tgf-β1, Gli1) in ethanol-exposed HSC-T6 rat hepatic stellate cells, and acts synergistically with anti-miR-96 to correct dysregulated gene expression[1].
MDB5 (1-100 μM; 48 h) potently inhibits the viability of HSC-T6 cells, with an IC50 of 25 μM after 48 h of incubation[2].
MDB5 (50 μM; 48 h) disrupts the cell cycle progression of HSC-T6 cells by increasing the proportions of cells in the G0/G1 and G2/M phases and decreasing the proportion of cells in the S phase[2].
MDB5 (50 μM; 48 h) potently downregulates components of the Hh pathway (GLI1, PTCH1), the metabolic enzyme GLS1, and the fibrosis marker α-SMA at both mRNA and protein levels in HSC-T6 cells[2].
MDB5 (50 μM; 24 h) significantly reduces the basal oxygen consumption rate of HSC-T6 cells, and this effect appears after 24 h of cell treatment with 50 μM, indicating that it inhibits mitochondrial metabolic activity. Meanwhile, it significantly suppresses glucose uptake by HSC-T6 cells[2].
Treatment with MDB5 (25 μM; 24 h) at the IC50 concentration of 25 μM for 24 h significantly reduces transglutaminase activity in HSC-T6 cells[2].
MDB5 (50 μM; 24 h) significantly inhibits fibronectin matrix assembly in HSC-T6 cells, and after treatment with 50 μM for 24 h, the matrix formation decreases to approximately 80% of that in the control group[2].
Micelle-encapsulated MDB5 (1-100 μM; 48 h) potently inhibits the viability of HSC-T6 cells in a dose-dependent manner[2].
MDB5-loaded PEG-PCC-g-DC micelles (up to 9.8% w/w; 60 h) exhibit a uniform spherical morphology with a particle size of 40-50 nm, a maximum drug loading capacity of 9.8% w/w, enhanced water solubility, and sustained drug release properties, with approximately 60% of the drug released within 24 h[2].
MDB5 exhibits the strongest binding affinity to wild-type human Smo protein, with a docking score of −12.84 kcal/mol, and forms unique additional interactions within the 7-TM domain[3].
MDB5 (0-100 μM; 72 h) potently reduces the viability of human pancreatic cancer cell line MIA PaCa-2, with an IC50 of 55.57 μM; it decreases the viability of human pancreatic cancer cell line PANC-1 in a dose-dependent manner[3].
MDB5 (incubated for 24 h after siRNA transfection; 50 μM) exerts cytotoxic effects on human pancreatic cancer cells MIA PaCa-2 via the Smo-dependent Hedgehog pathway, as its activity is completely abolished in Smo-knockdown cells[3].
MDB5 (50 μM; 72 h) effectively and significantly downregulates the expression of Hedgehog pathway transcripts (Gli-1, Gli-2, Ptch-1 and Shh) in human pancreatic cancer cell line MIA PaCa-2[3].
MDB5 (50 μM; 72 h) downregulates Hedgehog pathway proteins (Gli-1, Shh) and the anti-apoptotic protein Bcl-2, while upregulating the pro-apoptotic protein Bax in human pancreatic cancer cells MIA PaCa-2[3].
MDB5 (50 μM; 72 h) downregulates pancreatic cancer stem cell (CSC) markers (ALDH1/2, CD44, Oct-3/4) in the human pancreatic cancer cell line MIA PaCa-2[3].
MDB5 (50 μM; 72 h) downregulates Hedgehog pathway proteins (Gli-1, Shh) and the anti-apoptotic protein Bcl-2, while upregulating the pro-apoptotic protein Bax[3] in human pancreatic cancer cell line PANC-1.
MDB5 (50 μM; 72 h) induces S-phase cell cycle arrest in human pancreatic cancer cell line MIA PaCa-2, and 45.1% of MIA PaCa-2 human pancreatic cancer cells undergo apoptosis[3].
MDB5 (50 μM; 72 h post-seeding) significantly reduces the migratory potential of human pancreatic cancer cell line MIA PaCa-2[3].
MDB5 (50 μM; 7 days) significantly reduces the tumorigenic (colony-forming) potential of human pancreatic cancer cells MIA PaCa-2[3].
MDB5 (50 μM; applied on day 4 of spheroid culture) effectively reduces the volume of MIA PaCa-2 human pancreatic cancer 3D spheroids[3].
Nanoparticle-encapsulated MDB5 (10-100 μM; 72 h) reduces the viability of human pancreatic cancer cell line MIA PaCa-2 in a dose-dependent manner[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HSC-T6 rat hepatic stellate cells (ethanol-exposed)
-
Concentration:50 μM
-
Incubation Time:48 h
-
Result:Increased mRNA expression of Smad7 and decreased mRNA expression of Tgf-β1 and Gli1 compared to untreated or scrambled miRNA-transfected cells.
Showed significantly greater efficiency in correcting dysregulated gene expression when combined with anti-miR-96 than when used alone.
-
Cell Line:rat hepatic stellate cell line (HSC-T6)
-
Concentration:1-100 μM; 25 μM
-
Incubation Time:48 h
-
Result:Caused a significant dose-dependent decrease in HSC-T6 cell viability at 48 h.
Exhibited a 50% inhibitory concentration (IC50) of 25 μM.
Reduced cell viability at concentrations of 50 μM and 100 μM.
-
Cell Line:rat hepatic stellate cell line (HSC-T6)
-
Concentration:50 μM
-
Incubation Time:48 h
-
Result:Resulted in a significantly higher percentage of apoptotic cells (16.3%) untreated control cells.
-
Cell Line:rat hepatic stellate cell line (HSC-T6)
-
Concentration:50 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of cells in the G0/G1 phase to 57.25%, the percentage of cells in the G2/M phase to 12.9%, and decreased the percentage of cells in the S phase to 30.65%, compared to control cells (46.7% G0/G1, 7.86% G2/M, 45.62% S).
-
Cell Line:rat hepatic stellate cell line (HSC-T6)
-
Concentration:50 μM
-
Incubation Time:48 h
-
Result:Caused significant downregulation of GLI1, PTCH1, GLS1, and α-SMA mRNA expression relative to untreated control cells.
Significantly reduced protein levels of GLI1, PTCH1, GLS1, α-SMA, and YAP1.
-
Cell Line:rat hepatic stellate cell line (HSC-T6)
-
Concentration:1-100 μM
-
Incubation Time:48 h
-
Result:Caused a dose-dependent decrease in HSC-T6 cell viability at 48 h.
Showed enhanced efficacy compared to free MDB5 due to micellar formulation.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:0-100 μM
-
Incubation Time:72 h
-
Result:Reduced MIA PaCa-2 cell viability in a dose-dependent manner.
Achieved an IC50 value of 55.57 μM.
-
Cell Line:PANC-1 human pancreatic cancer cells
-
Concentration:0-100 μM
-
Incubation Time:72 h
-
Result:Reduced PANC-1 cell viability in a dose-dependent manner.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:post 24 h siRNA transfection incubation
-
Result:Showed no cytotoxic effect in MIA PaCa-2 cells transfected with Smo-specific siRNA.
Exhibited significant cytotoxicity in cells transfected with non-targeting control siRNA, matching results seen in untransfected cells.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Significantly reduced the relative expression of Gli-1, Gli-2, Ptch-1, and Shh transcripts.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Significantly reduced the protein levels of Gli-1, Shh, and the anti-apoptotic protein Bcl-2.
Increased the protein level of the pro-apoptotic protein Bax.\n
Significantly reduced the protein levels of pancreatic CSC markers ALDH1/2, CD44, and Oct-3/4.
-
Cell Line:PANC-1 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Significantly reduced the protein levels of Gli-1, Shh, and Bcl-2.
Increased the protein level of Bax.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Induced total apoptosis in 45.1% of MIA PaCa-2 cells.
Showed a significantly greater apoptotic effect than untreated control cells (5.7%).
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Significantly increased the percentage of cells in S-phase to 29.27%.
Significantly reduced the percentage of cells in G1-phase.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:50 μM
-
Incubation Time:72 h post-seeding
-
Result:Significantly reduced the number of migratory MIA PaCa-2 cells.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cells
-
Concentration:10-100 μM
-
Incubation Time:72 h
-
Result:Reduced MIA PaCa-2 cell viability in a dose-dependent manner.
Showed efficacy comparable to free MDB5.
In Vivo
MDB5 loaded micelles (10 mg/kg; i.v.; 3 times weekly; 2 weeks) exerts superior antifibrotic, hepatoprotective, and Hh pathway inhibitory effects compared to GDC-0449 in CBDL-induced liver fibrosis in C57BL/6 mice, including significant reductions in serum liver enzymes, collagen deposition, and Hh target gene expression, and restoration of liver sinusoidal structure[2].
MDB5 (20 mg/kg; i.v.; thrice weekly; 3 weeks) delivered via mPEG-b-P(CB-co-LA) nanoparticles significantly inhibits subcutaneous pancreatic tumor growth in NSG mice, reducing mean tumor volume to 103.56 mm3 with no systemic toxicity[3].
MDB5 (20-40 mg/kg; i.p.; thrice weekly; 4 weeks) administered via intraperitoneal emulsion at doses up to 40 mg/kg does not cause significant hepatic injury in NSG mice with subcutaneous pancreatic tumors[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male)[1]
-
Dosage:20 mg/kg (free MDB5); 20 mg/kg (MDB5 loaded in MDC2 LNPs)
-
Administration:i.v.; three times per week; 2 weeks
-
Result:Decreased plasma ALT levels to 58.76 U/L and AST levels to 111.5 U/L (MDB5 LNPs group).
Decreased plasma ALT to 70.7 U/L and AST to 137.5 U/L (free MDB5 group).
Reduced hepatic triglyceride levels to 28.3 mg/g (MDB5 LNPs group).
Reduced hepatic protein levels of GLI2 and SHH, restored hepatic FOXO3A staining, and decreased TGF-β1 staining (MDB5 LNPs group).
Reduced liver injury, hepatic steatosis, collagen deposition, and lipid accumulation (MDB5 LNPs group).
-
Animal Model:C57BL/6 wild-type (male, 8-10 weeks old, CBDL-induced liver fibrosis)[2]
-
Dosage:10 mg/kg
-
Administration:i.v.; 3 times a week; 2 weeks
-
Result:Significantly reduced serum levels of ALT, AST, TBIL, and ALP compared to CBDL control and GDC-0449 loaded micelles.
Restored normal liver morphology, reduced hepatic steatosis and lesions, and decreased collagen deposition more effectively than GDC-0449.
Significantly downregulated hepatic expression of Hh pathway components (GLI1, PTCH1), glutaminolysis enzyme GLS1, proliferation marker Ki-67, profibrogenic factor OPN, and mesenchymal marker α-SMA, while restoring epithelial marker E-cadherin expression.
Prevented liver sinusoidal endothelial capillarization, maintaining sinusoidal porosity comparable to sham mice.
Enhanced intrahepatic distribution of fluorescently labeled micelles compared to GDC-0449 loaded micelles.
Fully restored kidney histology and showed superior protective effects on spleen structural restoration relative to GDC-0449.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG) (male, 8-10 weeks old, subcutaneous injection of 3×106 MIA PaCa-2 cells to establish flank tumors)[3]
-
Dosage:20 mg/kg
-
Administration:i.v.; thrice weekly; 3 weeks
-
Result:Reduced final mean tumor volume to 103.56 mm3.
Decreased final mean tumor weight significantly compared to control and GDC-0449 groups.
Reduced Ki-67 staining in treated tumors relative to controls and GDC-0449-treated tumors.
Increased cleaved caspase-3 staining in treated tumors relative to controls and GDC-0449-treated tumors.
Increased E-cadherin staining in treated tumors relative to controls and GDC-0449-treated tumors.
Caused no significant changes in body weight during treatment.
Showed no pathological changes in major organs (kidney, spleen, liver, lung, heart) via H&E staining.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG) (male, subcutaneous flank tumors established with MIA PaCa-2 cells grown to 200 mm3)[3]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:i.p.; thrice weekly; 4 weeks
-
Result:Caused no significant changes in hepatic biochemical parameters (alanine aminotransferase, total bilirubin) compared to control mice at 20 mg/kg dose.
Caused no significant changes in hepatic biochemical parameters (alanine aminotransferase, total bilirubin) compared to control mice at 40 mg/kg dose.
Chemical Information
-
CAS No. 2922221-22-3
-
Molecular Weight 568.45
-
Formula C31H23Cl2N5O2
-
SMILES
O=C(C1=CC=C(C(N(CC2=NC=CC=C2)CC3=NC=CC=C3)=O)C=C1Cl)NC4=CC(C5=NC=CC=C5)=C(Cl)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ECM-Embedded Organoid (Matrigel/Dome) Culture
ECM-embedded organoid dome culture embeds epithelial stem cells, crypts, organoid fragments, or tumor-derived epithelial cells in a basement-membrane-like hydrogel such as Matrigel, allowing 3D growth, self-organization, lumen formation, budding or cystic morphogenesis, and lineage maintenance under defined niche-factor-containing medium. The primary readouts are organoid establishment efficiency, growth, morphology, passaging capacity, lineage-marker expression, and, when fluorescently labeled lines are used, microscopy- or flow-cytometry-based quantification of population behavior in 3D culture.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Matrigel Transwell/Boyden Chamber Invasion Assay
Matrigel Transwell/Boyden chamber invasion assay measures the ability of cells to degrade or traverse an extracellular matrix-coated porous membrane and move from an upper chamber toward a chemoattractant in a lower chamber. Invasion is distinguished from migration by coating the membrane with Matrigel or basement membrane matrix; uncoated inserts measure migration, while coated inserts require cells to cross an ECM barrier before reaching the underside of the membrane.
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Matrigel/ECM Transwell Invasion Assay
The Matrigel/ECM Transwell invasion assay measures the ability of cells to move toward a chemoattractant while crossing an extracellular-matrix barrier placed on a porous membrane; therefore, the readout reflects both chemotactic motility and matrix invasion rather than migration alone. Matrigel is a basement-membrane-rich matrix derived from Engelbreth-Holm-Swarm mouse sarcoma and has been used as a reconstituted basement membrane barrier in chemoinvasion assays. The assay readout is generated by quantifying cells that reach the underside of the insert membrane or lower compartment after incubation, commonly by staining and counting invaded cells or by fluorescence-based quantification.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Kumar V, et al. Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice. Biomaterials. 2023 Apr;295:122049. [Content Brief]
[2]. Kumar V, et al. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis. Theranostics. 2019;9(25):7537-7555. [Content Brief]
[3]. Kumar V, et al. Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Scientific reports. 2017 May 10;7(1):1665. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- MDB5
- 2922221-22-3
- MDB 5
- MDB-5
- Hedgehog
- Smo
- Apoptosis
- Bcl-2 Family
- liver fibrosis
- hepatic stellate cell
- MIA PaCa-2 human pancreatic cancer cell
- pancreatic cancer
- Hedgehog pathway
- HSC-T6 rat hepatic stellate cell
- PANC-1 human pancreatic cancer cell
- alcohol-associated liver disease
- Smoothened
- pancreatic cancer stem cell
- Inhibitor
- inhibitor
- inhibit